The DOI matches its Crossref record.
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Self-citationSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
Austin, M. A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh236 · Cited by 657
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
NARC-1/PCSK9 and Its Natural Mutants
Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.-C., Hamelin, J., Varret, M., Allard, D., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409699200 · Cited by 587
Self-citationA review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia
Marks, D., Thorogood, M., Neil, H. A. W., & Humphries, S. E. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00330-1 · Cited by 570
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18925 · Cited by 560
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Civeira, F. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.11.010 · Cited by 495
Self-citationGagné, C., Gaudet, D., & Bruckert, E. (2002) · Circulation · doi:10.1161/01.cir.0000018744.58460.62 · Cited by 482
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318925 · Cited by 450
Lambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., & Burnett, J. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.039 · Cited by 364
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., & Shattuck, D. M. (2004) · Human Genetics · doi:10.1007/s00439-003-1071-9 · Cited by 321
De Backer, G., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., Ebrahim, S., Faergeman, O., Graham, I., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention and Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 274
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl077 · Cited by 258
“For the gain-of-function mutation S127R, reduced number of LDLR has been found in Epstein Barr-virus (EBV)transformed lymphocytes (8), but not in fibroblasts (20) from patients heterozygous for the mutation.”
BackgroundAbifadel, M., Rabès, J.-P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009) · Human Mutation · doi:10.1002/humu.20882 · Cited by 256
Self-citationMutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
Leren, T. (2004) · Clinical Genetics · doi:10.1111/j.0009-9163.2004.0238.x · Cited by 255
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease
Nioi, P., Sigurdsson, A., Thorleifsson, G., Helgason, H., Agustsdottir, A. B., Norddahl, G. L., Helgadottir, A., Magnusdottir, A., Jonasdottir, A., Gretarsdottir, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508419 · Cited by 189
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Self-citationGenetics, Clinical Phenotype, and Molecular Cell Biology of Autosomal Recessive Hypercholesterolemia
Soutar, A. K., Naoumova, R. P., & Traub, L. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000094410.66558.9a · Cited by 99
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89
Garg, A., & Simha, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0275 · Cited by 89
Maxwell, K. N., & Breslow, J. L. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000162321.31925.a3 · Cited by 82
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Dron, J. S., & Hegele, R. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000386 · Cited by 72
Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
Naeli, P., Mirzadeh Azad, F., Malakootian, M., Seidah, N. G., & Mowla, S. J. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00189 · Cited by 58
A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1
The French Research Network on ADH, Marques-Pinheiro, A., Marduel, M., Rabès, J.-P., Devillers, M., Villéger, L., Allard, D., Weissenbach, J., Guerin, M., Zair, Y., et al. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.94 · Cited by 38
Self-citation
Metadata
- Authors
- Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., Kotze, M. J., Schmidt, H., Buzzi, J.-C., Kostner, G. M., Bertolini, S., Pocovi, M., Rosa, A., Farnier, M., Martinez, M., Junien, C., & Boileau, C.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 64
- Issue
- 5
- Pages
- 1378-1387
- ISSN
- 0002-9297 (ISSN-L)
- OpenAlex
- W1980786839
- Cited by
- 175
- References
- 0
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.